Last reviewed · How we verify
HEM1036 Phase 2 Study in Low Anterior Resection Syndrome
Double-blind, randomized, placebo controlled phase 2 study to explore the efficacy and safety of HEM1036 in the treatment of subjects with LARS
Details
| Lead sponsor | HEM Pharma Inc. |
|---|---|
| Phase | PHASE2 |
| Status | UNKNOWN |
| Enrolment | 67 |
| Start date | Mon Jan 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- LARS - Low Anterior Resection Syndrome
Interventions
- Lactobacillus Fermentum
- Placebo